Genotyping of Specific SNPs to Stratify Prostate Cancer Risk

Technology #ua16-162

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Ronald Heimark
Professor, Surgery
Jason Wilder
Assoc Professor & Chair, Biological Sciences
Kelsey Guest
Research Specialist, UACC
Virginia Ware
Managed By
Lisa Lin
Licensing Manager (520) 626-6969

Title: Genotyping of specific SNPs to stratify prostate cancer risk.

 

Invention: The technology are several SNP (single nucleotide polymorphism) markers with high potential of clinical utility to identify patients that will develop locally advanced stages of prostate cancer.

 

Background: The worldwide elderly population is experiencing an increase in prostate cancer. For prostate cancer prognosis, PSA levels and biopsy are sometimes inconclusive, leaving doctors and patients a difficult decision on whether to do a prostatectomy or not. These SNP markers (related to microRNA splicing) identified by the inventing team will help them to make a more informative decision. 

 

Applications:

  • Clinical prognosis markers to predict aggressive prostate cancer

 

Advantages:

  • Provides strong biomarkers to predict a patient’s risk on developing aggressive prostate cancer.
  • Aids in improving decision making for treatment options.

 

Licensing Manager: 

Lisa Lin

LisaL@tla.arizona.edu

(520) 626-6969